Oncotarget

Research Papers:

Prognostic value of the expression of cancer stem cell-related markers CD133 and CD44 in hepatocellular carcinoma: From patients to patient-derived tumor xenograft models

Qihong Zhao, Heng Zhou, Qifei Liu, Ye Cao, Gang Wang, Anla Hu, Liang Ruan, Sufang Wang, Qingli Bo, Wenjun Chen, Chuanlai Hu, Dexiang Xu, Fangbiao Tao, Jiyu Cao, Yongsheng Ge, Zongfan Yu, Li Li and Hua Wang _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:47431-47443. https://doi.org/10.18632/oncotarget.10164

Metrics: PDF 2833 views  |   HTML 2656 views  |   ?  


Abstract

Qihong Zhao1,*, Heng Zhou2,*, Qifei Liu1, Ye Cao1, Gang Wang4, Anla Hu1, Liang Ruan1, Sufang Wang1, Qingli Bo1, Wenjun Chen1, Chuanlai Hu1, Dexiang Xu1, Fangbiao Tao1, Jiyu Cao1, Yongsheng Ge5, Zongfan Yu6, Li Li1, Hua Wang2,3,7

1Department of Food and Nutrition Hygiene, School of Public Health, Anhui Medical University, Hefei, China

2School of Pharmacy, Anhui Medical University, Hefei, China

3Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China

4Department of Oncology, Affiliated Provincial Hospital of Anhui Medical University, Hefei, China

5Department of General Surgery, Affiliated Provincial Hospital of Anhui Medical University, Hefei, China

6Department of General Surgery, The Second Affiliated Hospital of Anhui Medical University, Hefei, China

7Institute for Liver Disease, Anhui Medical University, Hefei, China

*These authors contributed equally to this work

Correspondence to:

Li Li, email: [email protected]

Hua Wang, email: [email protected]

Keywords: prognostic value, cancer stem cell markers, hepatocellular carcinoma, patient-derived tumor xenograft models

Received: October 10, 2015     Accepted: June 06, 2016     Published: June 18, 2016

ABSTRACT

High expression of cancer stem cell (CSC) markers is related to poor prognosis of patients with hepatocellular carcinoma (HCC). However, the expression of these markers in patient-derived xenograft (PDX) models and the relationship of the expression levels of these markers between HCC patients and their PDX models at subsequent low passages are unclear. To investigate the prognostic impact of putative CSC markers in patients with HCC and in related PDX models, the expression of CD133, CD90, CD44, ALDH1, CK7, CK19, OCT4, SOX2, vimentin, nestin, CD13 and EpCam were assessed by quantitative reverse transcription-PCR (qRT-PCR) and then were validated using immunohistochemistry in tumor or peritumoral tissues from patients and tumor tissues from PDX models. Cumulative survival analysis of the patients and animals was conducted using the Kaplan-Meier method and the log-rank test. Only the expression levels of CD133 and CD44 were higher in tumor tissues than in the peritumoral tissues of HCC patients by qRT-PCR. High consistency of the prognostic value of the expression of CD133/CD44 was observed in HCC patients and the PDX models. High expression levels of CD133 and CD44 were positively related to the poor prognosis of HCC patients and to that in the PDX models. PDX HCC models in the present study have been suggested to be predictive of disease outcome, which could shed light on personalized medicine and the mechanisms of CSC marker expression on prognosis.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10164